Patents by Inventor Jim Li

Jim Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11208414
    Abstract: The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: December 28, 2021
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
  • Patent number: 11174261
    Abstract: The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: November 16, 2021
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
  • Publication number: 20210292289
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: October 5, 2020
    Publication date: September 23, 2021
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren
  • Publication number: 20210261573
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: January 20, 2021
    Publication date: August 26, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, JR., Lene Raunkjaer PETERSEN
  • Patent number: 11078228
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: August 3, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Lijing Chen, Roland Joseph Billedeau, Jim Li
  • Patent number: 11034715
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 15, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Roland J. Billedeau, Jim Li, Lijing Chen
  • Patent number: 11021495
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • Publication number: 20210061822
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 4, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE
  • Patent number: 10851118
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: December 1, 2020
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
  • Patent number: 10844080
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: November 24, 2020
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
  • Publication number: 20200339607
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: February 14, 2020
    Publication date: October 29, 2020
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Lene Raunkjær PETERSEN
  • Patent number: 10793535
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: October 6, 2020
    Assignee: Calithera Biosciences, Inc.
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
  • Publication number: 20200223872
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 16, 2020
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE
  • Publication number: 20200225330
    Abstract: Embodiments discussed herein refer to using LiDAR systems for steering consecutive light pulses using micro electro-mechanical system (MEMS) to illuminate objects in a field of view. Embodiments discussed herein also refer to using a multiple lens array to process returned light pulses.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 16, 2020
    Inventors: Rui Zhang, Yimin Li, Junwei Bao, Jim Li
  • Publication number: 20200223882
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 16, 2020
    Inventors: Roland J. Billedeau, Jim Li, Lijing Chen
  • Publication number: 20200165238
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: December 6, 2019
    Publication date: May 28, 2020
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric B. Sjogren
  • Patent number: 10597411
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: March 24, 2020
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • Publication number: 20200087310
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: September 27, 2019
    Publication date: March 19, 2020
    Inventors: Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
  • Patent number: 10570167
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 25, 2020
    Assignee: Calithera Biosciences, Inc.
    Inventors: Roland J. Billedeau, Jim Li, Lijing Chen
  • Patent number: 10472364
    Abstract: The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: November 12, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau